Breast CarcinomaNCT07126522
Virtual Support Platform (HERCaRE Application) for the Improvement of Survivorship Among Black Breast Cancer Survivors
A study testing Discussion, Internet-Based Intervention and Interview in people with Breast Carcinoma, run by Mayo Clinic at 1 site in United States.
Trial summary
This clinical trial studies how well a virtual support platform, the Health Equity Resources for Breast Cancer Responsive Education (HERCaRE) application (app), works in improving survivorship among Black survivors of breast cancer. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Breast Carcinoma
- What is being tested?
- Discussion, Internet-Based Intervention and Interview
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 45 participants
- Where
- 1 siteUnited States
- Study dates
- 18 Jul 2025to 2 Mar 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults aged 18 and older
- Self-identified Black women with a history of breast cancer
- "Self-identified Black woman" refers to individuals who personally identify as a Black or African American woman, inclusive of cisgender women from diverse cultural backgrounds. This will be confirmed during a verbal eligibility screening conducted prior to enrollment
- Completed active breast cancer treatment (e.g., surgery, chemotherapy, or radiation) at least one month prior to enrollment; survivors receiving long-term hormonal therapy are also eligible
- Reside within the Mayo Clinic Florida catchment area
- Have access to a smartphone or willingness to use alternative access points
- "Alternative access points" refer to non-clinical settings through which participants may be made aware of the study, including support groups, community health events, churches, and partner organizations that engage with breast cancer survivors outside of the traditional healthcare setting
Who cannot join
- Individuals without a history of breast cancer
- Those unable to provide verbal consent
- Individuals who lack the ability to engage with digital platforms, as determined during the screening process via brief questions assessing comfort and experience with mobile technology. Participants must be able to open the app, read content, and complete survey independently. iPads will be available for participants who do not have their own mobile device
Trial locations and contacts
1 site in 1 country.
United States1 site
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980
About this study
Official title: Advancing Survivorship Support Through Virtual Health Equity Resources for Breast Cancer Responsive Education (HERCaRE)
This clinical trial studies how well a virtual support platform, the Health Equity Resources for Breast Cancer Responsive Education (HERCaRE) application (app), works in improving survivorship among Black survivors of breast cancer. The HERCaRE platform is a mobile-friendly app that includes culturally tailored educational materials, interactive content, and health equity resources to help patients better understand and manage survivorship after breast cancer treatment. This trial may help improve how digital health interventions can enhance survivorship support and access to resources.
- Conditions
- Breast Carcinoma
- Being tested
- Discussion, Internet-Based Intervention, Interview, Survey Administration
- Medical subject headings
- Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DiscussionOther
Also called Discuss
Ancillary studies
Internet-Based InterventionOther
Use the HERCaRE app
InterviewOther
Ancillary studies
Survey AdministrationOther
Ancillary studies
| Study group | Role | What they receive |
|---|---|---|
| Supportive Care (HERCaRE app) | Experimental | Patients use the HERCaRE app over 4-6 weeks on study. Receives: Other: Discussion; Other: Internet-Based Intervention; Other: Interview; Other: Survey Administration |
What is being measured
The primary outcome is the main question the study is designed to answer.
Survivorship engagement - login
Assessed by active use of the Health Equity Resources for Breast Cancer Responsive Education (HERCaRE) platform, defined as number of logins per participant.
Measured: Up to 6 weeks
Survivorship engagement - time
Assessed by the length of time each participant spent using the HERCaRE platform.
Measured: Up to 6 weeks
Survivorship engagement - self-report
Assessed by self-reported actions such as initiating conversations with providers or accessing survivorship resources. Information will be obtained through semi-structured interviews.
Measured: Up to 6 weeks
Adherence to follow-up care
Assessed by participant self-reported scheduling or completion of appointments (e.g., mammograms, primary care physician visits). Information will be obtained through semi-structured interviews.
Measured: Up to 6 weeks
Secondary outcomes (2)
Participant satisfaction - HERCaRE Final Survey
Will be assessed by 5 question from a 9-question HERCaRE Final Survey. Three questions are answered on a 5-point scale (strongly agree, agree, neutral, disagree, strongly disagree), and two questions are open-ended/free text.
Measured: Up to 6 weeks
Perceived usability - HERCaRE Final Survey
Will be assessed by a 4 question of a 9-question HERCaRE Final Survey. Two questions are multiple choice (e.g., Yes, No, Not sure) Once is related to likelihood of taking follow-up actions such as "schedule and attend a follow-up appointment" or "ask more questions during my next visit." The final question is an open-ended/free text question related to any difficulties using the app or competing activities.
Measured: Up to 6 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Aug 2025
- Study start18 Jul 2025
- Primary completion2 Mar 2026
- Study completion2 Mar 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast CarcinomaStudies of the same condition, open and under way.
- More trials run by Mayo ClinicThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 45 participants (actual)
Sponsor and investigators
- Lead sponsor
- Mayo Clinic
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Manisha Salinas, DrPH, Principal investigator, Mayo Clinic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07126522
- Sponsor's protocol ID
- 25-001524
- Other IDs
- NCI-2025-05318, 25-001524
- Status last verified
- Mar 2026
- First submitted
- 11 Aug 2025
- Last updated
- 30 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Advancing Survivorship Support Through Virtual Health Equity Resources for Breast Cancer Responsive Education (HERCaRE)
- ClinicalTrials.gov ID
- NCT07126522
- Acronym / sponsor ID
- 25-001524
- Conditions
- Breast Carcinoma
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 45 participants (actual)
- Lead sponsor
- Mayo ClinicUniversity, hospital or other
- Study start
- 18 Jul 2025 (actual)
- Primary completion
- 2 Mar 2026 (actual)
- Study completion
- 2 Mar 2026 (actual)
- First posted
- 17 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This clinical trial studies how well a virtual support platform, the Health Equity Resources for Breast Cancer Responsive Education (HERCaRE) application (app), works in improving survivorship among Black survivors of breast cancer. The HERCaRE platform is a mobile-friendly app that includes culturally tailored educational materials, interactive content, and health equity resources to help patients better understand and manage survivorship after breast cancer treatment. This trial may help improve how digital health interventions can enhance survivorship support and access to resources.
Study design
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Supportive Care (HERCaRE app) | Experimental | Other: Discussion, Other: Internet-Based Intervention, Other: Interview, Other: Survey AdministrationPatients use the HERCaRE app over 4-6 weeks on study. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Adults aged 18 and older
- Self-identified Black women with a history of breast cancer
- Completed active breast cancer treatment (e.g., surgery, chemotherapy, or radiation) at least one month prior to enrollment; survivors receiving long-term hormonal therapy are also eligible
- Reside within the Mayo Clinic Florida catchment area
- Have access to a smartphone or willingness to use alternative access points
Key exclusion criteria (3 listed)
- Individuals without a history of breast cancer
- Those unable to provide verbal consent
- Individuals who lack the ability to engage with digital platforms, as determined during the screening process via brief questions assessing comfort and experience with mobile technology. Participants must be able to open the app, read content, and complete survey independently. iPads will be available for participants who do not have their own mobile device
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| DiscussionAlso: DiscussAncillary studies | Other | Supportive Care (HERCaRE app) |
| Internet-Based InterventionUse the HERCaRE app | Other | Supportive Care (HERCaRE app) |
| InterviewAncillary studies | Other | Supportive Care (HERCaRE app) |
| Survey AdministrationAncillary studies | Other | Supportive Care (HERCaRE app) |
Primary outcome
Survivorship engagement - login
Time frame: Up to 6 weeks
Assessed by active use of the Health Equity Resources for Breast Cancer Responsive Education (HERCaRE) platform, defined as number of logins per participant.
Survivorship engagement - time
Time frame: Up to 6 weeks
Assessed by the length of time each participant spent using the HERCaRE platform.
Survivorship engagement - self-report
Time frame: Up to 6 weeks
Assessed by self-reported actions such as initiating conversations with providers or accessing survivorship resources. Information will be obtained through semi-structured interviews.
Adherence to follow-up care
Time frame: Up to 6 weeks
Assessed by participant self-reported scheduling or completion of appointments (e.g., mammograms, primary care physician visits). Information will be obtained through semi-structured interviews.
2 secondary outcomes
Participant satisfaction - HERCaRE Final Survey
Time frame: Up to 6 weeks
Perceived usability - HERCaRE Final Survey
Time frame: Up to 6 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Mar 2026.
- Mayo Clinic Clinical TrialsLink provided by the sponsor.
Related trials for Breast Carcinoma
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Manisha Salinas, DrPH principal investigator
Mayo Clinic
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Discussion, Internet-Based Intervention and Interview in people with Breast Carcinoma, run by Mayo Clinic at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Survivorship engagement - login (time frame: Up to 6 weeks). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Mar 2026.